DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Trends in Biosimilars Market

Despite biosimilars being available for over ten years in some markets, the biosimilars market continues to evolve. Development of biosimilars is a truly global endeavour, helped by the spread of regulatory guidance. In this white paper, we explore the biosimilar R&D landscape, physician attitudes towards biosimilars, and drivers to prescribe, as well as two case studies on the launch dynamics of Sandoz’s Zarxio and Pfizer’s Inflectra in the United States.